Cancer Research;PARP Inhibition

AACR: PARP1-selective inhibitor demonstrates early efficacy in breast cancers with DNA repair defects

[ad_1] ABSTRACT CT014 Newswise — SAN DIEGO – The first-in-class PARP1-selective inhibitor saruparib demonstrated encouraging early efficacy and a favorable…